By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitochondrial DNA diagnostic test firm Mitomics today announced that QDx Pathology Services will develop, market, and process the QPredict Prostate Mitomic Test.

The test will be based on Mitomics' Prostate Core Mitomic Test, which Mitomics launched in March. Under the non-exclusive agreement, QDx Pathology will leverage its network of pathologists, urologists, and processing centers to expand the availability of the technology in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.

Wired writes that CRISPR could change the world — in many imaginative ways — and whether it will be for the better is still in the air.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.